Nadia Waheed
Chief Tech/Sci/R&D Officer at GYROSCOPE THERAPEUTICS HOLDINGS PLC
Profile
Nadia Waheed is currently the Chief Medical Officer at Beacon Therapeutics (USA), Inc. and Gyroscope Therapeutics Holdings Plc.
Prior to her current positions, she worked as the Director at Boston Image Reading Center LLC from 2015 to 2020.
She holds a graduate degree from Harvard T.H.
Chan School of Public Health and a doctorate degree from Aga Khan University.
Nadia Waheed active positions
| Companies | Position | Start |
|---|---|---|
| GYROSCOPE THERAPEUTICS HOLDINGS PLC | Chief Tech/Sci/R&D Officer | 2020-01-31 |
| APPLIED GENETIC TECHNOLOGIES CORPORATION | Chief Tech/Sci/R&D Officer | 2022-11-30 |
Former positions of Nadia Waheed
| Companies | Position | End |
|---|---|---|
| Boston Image Reading Center LLC | Director/Board Member | 2019-12-31 |
Training of Nadia Waheed
| Harvard T.H. Chan School of Public Health | Graduate Degree |
| Aga Khan University | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Private companies | 3 |
|---|---|
Beacon Therapeutics (USA), Inc.
 Beacon Therapeutics (USA), Inc. Pharmaceuticals: GenericHealth Technology Applied Genetic Technologies Corp. is a clinical stage biotechnology company, which engages in the usage of a gene therapy platform to develop transformational genetic therapies for patients suffering from rare and debilitating diseases. The firm also focuses on conducting clinical trials in the field of ophthalmology, optogenetics, adrenoleukodystrophy, and otology. The company was founded by Richard Jude Samulski, Nicholas Muzyczka, William W. Hauswirth, Terence R. Flotte, and Barry J. Byrne on January 19, 1999 and is headquartered in Alachua, FL. | Health Technology |
| Boston Image Reading Center LLC | |
Gyroscope Therapeutics Holdings Plc
 Gyroscope Therapeutics Holdings Plc BiotechnologyHealth Technology Gyroscope Therapeutics Holdings Plc engages in the development of gene therapy beyond rare diseases. It focuses on age-related macular degeneration. The company was founded in 2016 and is headquartered in Stevenage, the United Kingdom. | Health Technology |
- Stock Market
- Insiders
- Nadia Waheed
